Chlormezanone

DB01178ApprovedWithdrawnSmall molecule

A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.

Mechanism: Chlormezanone binds to central benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
Curator reviewed
Primary indication: Used in the management of anxiety and in the treatment of muscle spasm.Curator reviewed
Formula / weight: C₁₁H₁₂ClNO₃S · 273.736 g/mol (avg)
Also known as: Chlormethazanone

Resolves to

Compound

UNIIGP568V9G19CAS80-77-3ChEMBLCHEMBL1200714ChEBI3619PubChem2717KEGGD00268

Clinical / RWD

RxNorm2373ATCM03BB02ATCM03BB52ATCM03BB72PharmGKBPA448939

Structure

InChIKeyWEQAYVWKMWHEJO-UHFFFAOYSA-NSMILESCN1C(C2=CC=C(Cl)C=C2)S(=O)(=O)CCC1=O

Targets

P30536TSPO

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,130Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

3ATC codesIncluding every combination product, plus 15 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Chlormezanone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In